(Albany, USA) DelveInsight’s “Vasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Vasomotor Symptoms, historical and forecasted epidemiology as well as the Vasomotor Symptoms market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Vasomotor Symptoms market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Vasomotor Symptoms market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Vasomotor Symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Vasomotor Symptoms market.
To Know in detail about the Vasomotor Symptoms market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vasomotor Symptoms Market Forecast
Some of the key facts of the Vasomotor Symptoms Market Report:
- The Vasomotor Symptoms market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
- In February 2024, Mithra Pharmaceuticals announced a significant milestone in its clinical research efforts for DONESTA, a hormone therapy utilizing estetrol (E4) to treat moderate to severe vasomotor symptoms (Vasomotor symptoms) associated with menopause. The last patient-out mark was reached in the C301 Endometrial Safety Study, signaling the completion of patient treatments and the initiation of the data management and reporting phase.
- As per DelveInsight analysis, the menopause market size in the 7MM was approximately USD 11 billion in 2022.
- In the 7MM, the highest number of prevalent cases of vasomotor symptoms was observed in the United States.
- According to the assessment done by DelveInsight, the total number of women in menopause in the 7MM comprised approximately 100 million cases in 2022 and are projected to increase during the forecast period.
- Key Vasomotor Symptoms Companies: Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others
- Key Vasomotor Symptoms Therapies: Transdermal Estradiol Cream (VML-0203), DONESTA (E4, Estetrol), Elinzanetant (BAY3427080), MT-8554 (Elismetrep), MNGX-100 (Filgrastim/G-CSF), Q-122 (MSX-122), FP-101, and others
- The Vasomotor Symptoms market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vasomotor Symptoms pipeline products will significantly revolutionize the Vasomotor Symptoms market dynamics.
Vasomotor Symptoms Overview
Vasomotor symptoms (Vasomotor symptoms), commonly associated with menopause, are characterized by hot flashes and night sweats. These symptoms are caused by dysregulation in the hypothalamus, which controls body temperature, and are linked to fluctuating estrogen levels during the menopausal transition. Vasomotor symptom can vary in frequency and intensity, with episodes lasting from seconds to several minutes.
Hot flashes, the hallmark of Vasomotor symptoms, present as sudden waves of heat often accompanied by flushing, sweating, and an increased heart rate. Night sweats, their nocturnal counterpart, can disrupt sleep, leading to fatigue and diminished quality of life. Although most common during menopause, Vasomotor symptoms may also occur in other situations, such as following oophorectomy or cancer treatments that affect hormonal balance.
The prevalence of Vasomotor symptoms varies globally, influenced by genetics, lifestyle, and cultural factors. While Vasomotor symptoms typically decline within a few years post-menopause, some women experience symptoms for a decade or longer. Management strategies include lifestyle modifications, hormone replacement therapy (HRT), and non-hormonal treatments like selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT). Emerging therapies, such as neurokinin receptor antagonists, offer promising alternatives for women seeking relief from Vasomotor symptoms. Early intervention and tailored treatments can significantly enhance patient well-being.
Request for sample report @ Vasomotor Symptoms Treatment Market
Vasomotor Symptoms Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
DelveInsight estimates that there were approximately 100 million total women in menopause in the 7MM in 2022.
For the age-specific analysis, the number of cases of menopause were distributed across various age groups, such as
Vasomotor Symptoms Epidemiology Segmentation:
The Vasomotor Symptoms market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Number of Women in Menopause
- Stage-Specific Distribution of Women in Menopause
- Age-Specific Distribution of Women in Menopause
- Number of Women in Menopause with Vasomotor Symptoms
- Number of Women in Menopause with Moderate-to-Severe Vasomotor Symptoms
Download the report to understand which factors are driving Vasomotor Symptoms epidemiology trends @ Vasomotor Symptoms Epidemiology Forecast
Vasomotor Symptoms Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vasomotor Symptoms market or expected to get launched during the study period. The analysis covers Vasomotor Symptoms market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Vasomotor Symptoms Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Vasomotor Symptoms Therapies and Key Companies
- Transdermal Estradiol Cream (VML-0203): Viramal Limited/Simbec Research
- DONESTA (E4, Estetrol): Estetra/Mithra Pharmaceuticals
- Elinzanetant (BAY3427080): Bayer|Nerre Therapeutics Ltd.
- MT-8554 (Elismetrep): Mitsubishi Tanabe Pharma America Inc.
- MNGX-100 (Filgrastim/G-CSF): MenoGeniX
- Q-122 (MSX-122): QUE Oncology
- FP-101: Fervent Pharmaceuticals
Discover more about therapies set to grab major Vasomotor Symptoms market share @ Vasomotor Symptoms Drugs Market
Vasomotor Symptoms Treatment Market
The North American Menopause Society (NAMS) advises waiting until hot flashes become bothersome before seeking treatment. Treatment initiation should consider the severity of symptoms, evaluation of treatment risks, and the woman’s perspective on menopause and medication. Duavee (bazedoxifene acetate/conjugated estrogens) is the initial and sole medication combining CE with an estrogen agonist/antagonist, recognized as a selective estrogen receptor modulator (SERM), for menopausal Vasomotor symptoms treatment. Duavee incorporates bazedoxifene instead of progestin to safeguard the uterine lining against hyperplasia, a potential consequence of estrogen-only therapy.
Numerous women opt for non-prescription therapies like isoflavones, black cohosh, and progesterone-containing hormone creams to manage conditions like hot flashes. However, clinical evidence regarding the efficacy and long-term safety of these therapies remains inadequate. Moreover, most over-the-counter remedies for hot flashes are classified as dietary supplements and hence not regulated by the US Food and Drug Administration. Prescription medications with demonstrated efficacy in alleviating hot flashes are available for women unable to undergo hormone therapy. Certain prescription antidepressants, including those suitable for women with a history of breast cancer, may diminish hot flashes. Others include gabapentin, clonidine, and methyldopa. NAMS suggests that women experiencing mild menopause-related hot flashes initially consider lifestyle modifications such as adjusting environmental conditions for cooler core body temperatures, engaging in regular exercise, quitting smoking, and employing relaxation techniques such as paced respiration.
Vasomotor Symptoms Market Dynamics
The dynamics of the menopause market are experiencing notable changes due to the increasing societal awareness of women’s health and well-being. With a growing aging population and a heightened focus on women’s empowerment, there’s a rising demand for innovative products and services that address the physical and emotional difficulties associated with menopause. This surge in demand has led to increased research and development efforts, resulting in a diverse array of hormone replacement therapies, herbal supplements, lifestyle applications, and personalized health strategies.
As more women seek comprehensive and effective solutions, companies are adopting a more consumer-centric approach, tailoring their offerings to individual preferences and needs. Moreover, discussions surrounding menopause are becoming less taboo, fostering open dialogue and knowledge-sharing, which further shapes the dynamics of the menopause market by creating a supportive environment for women navigating this stage of life.
However, despite the potential for growth, the menopause market faces several barriers. Strict regulatory processes governing hormonal treatments and supplements, alongside concerns regarding product safety and effectiveness, present challenges for new entrants into the menopause market. Additionally, cultural stigmas and misinformation surrounding menopause persist in certain societies, hindering open conversations and the adoption of innovative solutions. Economic disparities and limited access to healthcare exacerbate these challenges, impeding equal penetration of the menopause market. Overcoming these barriers necessitates a multifaceted approach involving education, regulatory reforms, and inclusive product development to fully harness the potential of the menopause market.
Request for sample report to know more about therapies and drugs @ Vasomotor Symptoms Clinical Trials and Advancements
Scope of the Vasomotor Symptoms Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Vasomotor Symptoms Companies: Viramal Limited, Simbec Research, Estetra, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics Ltd., Mitsubishi Tanabe Pharma America Inc., MenoGeniX, QUE Oncology, Fervent Pharmaceuticals, and others
- Key Vasomotor Symptoms Therapies: Transdermal Estradiol Cream (VML-0203), DONESTA (E4, Estetrol), Elinzanetant (BAY3427080), MT-8554 (Elismetrep), MNGX-100 (Filgrastim/G-CSF), Q-122 (MSX-122), FP-101, and others
- Vasomotor Symptoms Therapeutic Assessment: Vasomotor Symptoms current marketed and Vasomotor Symptoms emerging therapies
- Vasomotor Symptoms Market Dynamics: Vasomotor Symptoms market drivers and Vasomotor Symptoms market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Vasomotor Symptoms Unmet Needs, KOL’s views, Analyst’s views, Vasomotor Symptoms Market Access and Reimbursement
Table of Contents
1. Vasomotor Symptoms Market Report Introduction
2. Executive Summary for Vasomotor Symptoms
3. SWOT analysis of Vasomotor Symptoms
4. Vasomotor Symptoms Patient Share (%) Overview at a Glance
5. Vasomotor Symptoms Market Overview at a Glance
6. Vasomotor Symptoms Disease Background and Overview
7. Vasomotor Symptoms Epidemiology and Patient Population
8. Country-Specific Patient Population of Vasomotor Symptoms
9. Vasomotor Symptoms Current Treatment and Medical Practices
10. Vasomotor Symptoms Unmet Needs
11. Vasomotor Symptoms Emerging Therapies
12. Vasomotor Symptoms Market Outlook
13. Country-Wise Vasomotor Symptoms Market Analysis (2020–2034)
14. Vasomotor Symptoms Market Access and Reimbursement of Therapies
15. Vasomotor Symptoms Market Drivers
16. Vasomotor Symptoms Market Barriers
17. Vasomotor Symptoms Appendix
18. Vasomotor Symptoms Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services